Dr. Peter J. Kushner Ph.D. is the Chief Scientific Officer at Olema Pharmaceuticals.
As the Chief Scientific Officer of Olema Pharmaceuticals, the total compensation of Dr D at Olema Pharmaceuticals is $429,952. There are 4 executives at Olema Pharmaceuticals getting paid more, with Dr. Sean P. Bohen M.D., Ph.D. having the highest compensation of $999,300.
Dr D is 82, he's been the Chief Scientific Officer of Olema Pharmaceuticals since . There are no older and 8 younger executives at Olema Pharmaceuticals.
Peter's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO, CA, 94107.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham a Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: